Mirtazapine
Mirtazapine, Remeron (mirtazapine) is a small molecule pharmaceutical. Mirtazapine was first approved as Remeron on 1996-06-14. It is used to treat depressive disorder in the USA. The pharmaceutical is active against alpha-2C adrenergic receptor, 5-hydroxytryptamine receptor 2C, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 2A, and alpha-2A adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Remeron, Remeron soltab (generic drugs available since 2003-01-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mirtazapine | ANDA | 2024-10-02 |
| remeron | New Drug Application | 2024-04-04 |
| remeron remeronsoltab | New Drug Application | 2024-03-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| depressive disorder | EFO_1002014 | D003866 | F32.A |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 1 | 13 | 6 | 17 | 17 | 53 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 11 | 4 | 18 | 11 | 45 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 8 | 4 | 13 | 8 | 34 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 2 | 1 | 7 | 1 | 1 | 12 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | 4 | 1 | — | 6 |
| Vomiting | D014839 | HP_0002013 | R11.1 | 2 | 2 | — | 1 | — | 4 |
| Nausea | D009325 | HP_0002018 | R11.0 | 2 | 2 | — | 1 | — | 4 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | 1 | 1 | 1 | 3 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | 2 | 1 | 3 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 2 | 1 | 3 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anorexia | D000855 | HP_0002039 | R63.0 | — | 6 | 1 | — | 1 | 7 |
| Neoplasms | D009369 | — | C80 | 1 | 3 | 2 | — | — | 5 |
| Sleep wake disorders | D012893 | — | G47 | — | — | 5 | — | — | 5 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | 4 | 1 | — | — | 4 |
| Parasomnias | D020447 | — | G47.5 | — | — | 4 | — | — | 4 |
| Dyssomnias | D020920 | — | — | — | — | 4 | — | — | 4 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | — | 1 | 1 | — | 1 | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 2 | — | 1 | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | 1 | — | 1 | 3 |
| Wasting syndrome | D019282 | — | — | — | 3 | 1 | — | — | 3 |
Show 19 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | — | 2 | 4 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 4 | — | — | — | 4 |
| Body weight | D001835 | EFO_0004338 | — | — | 2 | — | — | 2 | 4 |
| Weight loss | D015431 | HP_0001824 | — | — | 2 | — | — | 2 | 4 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | 3 | — | — | — | 3 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 1 | — | — | 1 | 2 |
| Dysthymic disorder | D019263 | EFO_0008623 | F34.1 | — | 2 | — | — | — | 2 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | 1 | 1 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | 1 | 2 |
| Hyperemesis gravidarum | D006939 | EFO_1000971 | O21 | 1 | 2 | — | — | — | 2 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Cardiovascular abnormalities | D018376 | EFO_0003848 | — | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 1 | — | — | — | — | 1 |
| Apnea | D001049 | HP_0002104 | R06.81 | 1 | — | — | — | — | 1 |
| Stomach diseases | D013272 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Spinal stenosis | D013130 | EFO_0007490 | M48.0 | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | — | — | 1 | 1 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 1 | 1 |
| Alcohol-related disorders | D019973 | — | F10 | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 1 | 1 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mirtazapine |
| INN | mirtazapine |
| Description | Mirtazapine is a benzazepine and a tetracyclic antidepressant. It has a role as an alpha-adrenergic antagonist, a serotonergic antagonist, a histamine antagonist, an anxiolytic drug, a H1-receptor antagonist and a oneirogen. |
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN2c3ncccc3Cc3ccccc3C2C1 |
Identifiers
| PDB | — |
| CAS-ID | 61337-67-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL654 |
| ChEBI ID | 6950 |
| PubChem CID | 4205 |
| DrugBank | DB00370 |
| UNII ID | A051Q2099Q (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA2C
ADRA2C
HTR2C
HTR2C
ADRA2B
ADRA2B
HTR2A
HTR2A
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2C
Gene synonyms
ADRA2L2, ADRA2RL2
NCBI Gene ID
Protein name
alpha-2C adrenergic receptor
Protein synonyms
adrenergic, alpha-2C-, receptor, Alpha-2 adrenergic receptor subtype C4, Alpha-2C adrenoceptor, Alpha-2C adrenoreceptor, Alpha-2CAR, alpha2-AR-C4
Uniprot ID
Mouse ortholog
Adra2c (11553)
alpha-2C adrenergic receptor (Q01337)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Remeron – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Mirtazapine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,106 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mirtazapine, Remeron, Remeron remeronsoltab
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
37,599 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use